Ara
Toplam kayıt 16, listelenen: 11-16
Thyroid Medullary Carcinoma In A Patient With Hiv/Aids
(Akad Doktorlar Yayınevi, 2012)
According to the clinical trials HIV positivity does not increase the frequency of thyroid malignancies. We present a patient with HIV positivity and thyroid medullary carcinoma. To our knowledge this is the second case ...
Striking Promotion Of The In Vitro Myeloma Monoclonal Immunoglobulin Aggregation By Ankaferd Hemostat
(Akad Doktorlar Yayınevi, 2012)
Ankaferd Blood Stopper (ABS) is a novel topical hemostatic agent. ABS-induced formation of the protein network with vital erythroid aggregation covers the entire physiological hemostatic process. ABS has pleiotropic cellular, ...
The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
(Akad Doktorlar Yayınevi, 2012)
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose ...
Is Sparing the Deep Lobes of Parotid Gland Necessary on Intensity Modulated Radion Therapy of Head and Neck Cancers?
(Akad Doktorlar Yayınevi, 2012)
RT to the lymphatics of the neck is an essential component in squamous cell cancers of the head and neck (SCCHN). Radiation induced mouth dryness, thickening of saliva and taste alteration affects nutrition and performance ...
Effects Of Ankaferd Blood Stopper On Nerve Conductance: An Experimental Study On The Rat Sciatic Nerve
(Akad Doktorlar Yayınevi, 2012)
The aim of this study was to evaluate the effect of AnkaferdBloodStopper(R) (ABS) on nerve conductance. ABS consists of traditional haemostatic ingredients, and has been officially approved for topical use in the management ...
Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in Cml
(Akad Doktorlar Yayınevi, 2012)
Dasatinib is considered an effective treatment agent in imatinib-resistant and newly diagnosed chronic phase CML patients. Patients receiving dasatinib 100 mg once daily regime suffered significantly fewer thrombocytopenia ...